Global priority pathogens: virulence, antimicrobial resistance and prospective treatment options

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Key Gram-positive and Gram-negative bacteria, including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp., and Salmonella spp., are significant global health threats.
• The rise of multidrug-resistant (MDR) strains among these pathogens exacerbates their impact, leading to increased morbidity and mortality.
• Bacterial virulence factors, such as toxin production and biofilm formation, contribute to host colonization and infection severity, necessitating novel therapeutic approaches.

Purpose of the Study:

• To provide an updated review of the epidemiology, virulence, and resistance patterns of clinically significant multidrug-resistant bacteria.
• To explore emerging therapeutic strategies for combating these challenging pathogens.
• To highlight antivirulence molecules as a promising avenue for developing new treatments against MDR bacteria.

Main Methods:

• Comprehensive literature review of recent studies on the selected pathogens.
• Analysis of epidemiological data, virulence mechanisms, and antibiotic resistance trends.
• Evaluation of novel therapeutic strategies, focusing on antivirulence compounds.

Main Results:

• The review consolidates current knowledge on the epidemiology, virulence factors, and resistance mechanisms of major MDR pathogens.
• Identified key virulence factors contributing to host colonization and disease.
• Highlighted the potential of antivirulence molecules to circumvent existing resistance mechanisms.

Conclusions:

• Multidrug-resistant bacteria pose a critical threat requiring urgent development of new therapeutic strategies.
• Antivirulence therapies represent a promising approach to combat MDR infections by targeting bacterial pathogenicity rather than viability.
• Further research into antivirulence molecules is essential for developing effective treatments against multidrug-resistant bacterial infections.